The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic
4 DISCUSSION
Through different subprotocols, patients received targeted agents or immunotherapy/novel agents in combination with a
We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs
POM-based therapy has emerged as an important treatment strategy for patients with LEN- and PI-refractory MM
Giving ixazomib citrate in addition to pomalidomide, dexamethasone, and stem cell transplantation may work better in treating patients with relapsed or refractory multiple myeloma
The study IFM 2014-01 /IxPd in HR L2 RRMM met its primary end point objective since the median TTP was superior to 3 months, the median TTP reported in IFM2010-02 as a whole, with the addition of Ixazomib to Pomalidomide and dexamethasone in this population characterized with a very poor outcome
At the same time, the second dose cohort was 3 mg of ixazomib and 4 mg of pomalidomide, and then the third dose cohort was at 4 mg for both, and we adjusted the steroids, as
This study assessed the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara-Ixa-dex) as second-line therapy in pts with RRMM who have been previously treated with a lenalidomide-based regimen
Patients continue on therapy until disease progression, intolerability or preference
Return to ≥ 30 x 109/L Resume treatment
This publication is part of our Treatment Guide series, a collection of publications covering different drugs used in the treatment of myeloma
Absolute neutrophil count < 0